P3-treated PAMs uniquely activated TGF-beta signaling and chronic myeloid leukemia pathways, indicating possible links to immunosuppressive or leukemogenesis-related processes, while P4-treated PAMs showed broader enrichment in pathways such as NF-κB signaling pathway, B cell receptor signaling pathway, propanoate metabolism, and choline metabolism in defensive immunity. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.